Family Med

Your Article Summary

See Latest Articles

Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice
Current Medical Research and Opinion, 10/22/09

Gandhi SK et al. – There is a strong and consistent body of evidence demonstrating the effectiveness of rosuvastatin in lowering LDL–C and LDL–C goal attainment in real life compared with other statins at commonly prescribed doses, which reflects the existing evidence from clinical trials.

• A comprehensive Medline literature search identified all published articles, in all languages, from January 2003 through September 2008 on the use of rosuvastatin in the usual–care setting.
• The search identified 60 articles, and 16 articles were included in this review because they were observational and non–interventional and included sufficient data specific to rosuvastatin.
• Excluded articles were clinical trials, cost–effectiveness models, safety, reviews, pharmacokinetics, abstracts or editorials only, or all statins combined.
• Included rosuvastatin articles were categorized as (1) effectiveness in general population and (2) effectiveness in special populations (e.g., elderly, diabetes).

• 7 studies consistently showed that diverse patients from different geographic regions who were newly initiated on rosuvastatin had significantly greater reduction in low–density lipoprotein cholesterol (LDL–C) (29–52%) compared with patients treated with other statins (16–43%).
• LDL–C goal attainment as recommended by National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III was consistently and significantly higher among patients treated with rosuvastatin (64–81%) compared with patients treated with other statins (34–73%).
• Rosuvastatin–treated patients with diabetes or HIV or who were elderly had significantly greater LDL–C reduction and LDL–C goal attainment compared with patients treated with other statins.
• Limitations: channeling bias or confounding by indication may have influenced the results of the real–world studies, if physicians reserve rosuvastatin for sicker or more difficult to treat patients.

Related Articles

See all related articles

Management of Hypercholesterolemia
Geriatrics & Aging, 11/12/09    Relevance Score: 83%

Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA
Expert Review of Cardiovascular Therapy, 11/16/09    Relevance Score: 80%

Study Demonstrates LIVALO Is an Efficacious Treatment for Achieving Lipid Goals
Internet Source, 10/23/09    Relevance Score: 80%

FDA approves Crestor for high cholesterol kids
Internet Source, 10/20/09    Relevance Score: 80%

FDA approves Crestor for high cholesterol kids
Internet Source, 10/19/09    Relevance Score: 80%

Today in Atherosclerosis/Lipids...keeping you current

Receive free subspecialty "5-minute updates" via email

Cardiovascular and Economic Outcomes After Initiation of Lipid-Lowering Therapy With Atorvastatin vs Simvastatin in an Employed Population
Mayo Clinic Proceedings, 12/11/09

Subclinical Atherosclerosis In Young beta-thalassemia Major Patients
Hemoglobin, 12/11/09

Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination: A Phase 3, Open-Label, Extension Study
Clinical Drug Investigation, 12/11/09

 See all of Atherosclerosis/Lipids

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus
Translational Research, The Journal of Laboratory and Clinical Medicine, 12/11/09

Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Pediatrics, 12/11/09

Emerging technologies in the delivery of erythropoietin for therapeutics
Medicinal Research Reviews, 12/11/09

 See all of Clinical Pharmacology